---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009220"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:14:08.815582+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# MyMD Pharmaceuticals reincorporates from New Jersey to Delaware

## Summary
- Merger effective March 4, 2024; no change in company name, business, management, or fiscal year.
- Stockholders approved reincorporation at 2023 annual meeting; common stock retains same CUSIP and symbol MYMD.
- No exchange of stock certificates required; shares automatically convert on a 1:1 basis.
- Rights of stockholders now governed by Delaware General Corporation Law.

## SEC filing metadata
- accession: 0001493152-24-009220
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315224009220/0001493152-24-009220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315224009220/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009220
- JSON: https://secwatch.observer/filing/0001493152-24-009220.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009220.txt

## Key facts
- Material Agreements
  Q/C TECHNOLOGIES, INC. entered into Plan of Merger with MyMD New Jersey, MyMD Delaware (effective 2024-03-04).
  - Action: entry
  - Agreement: merger
  - Counterparty: MyMD New Jersey, MyMD Delaware
  - Effective: 2024-03-04
  source text: MyMD Pharmaceuticals, Inc., a New Jersey corporation (“MyMD New Jersey” or, prior to the Reincorporation (as defined below), the “Company”) merged with and into its wholly-owned subsidiary, MyMD Pharmaceuticals, Inc., a Delaware corporation (“MyMD Delaware” or, following the Reincorporation, the “Company”), with MyMD Delaware being the surviving corporation, pursuant to that certain Agreement and Plan of Merger, dated as of March 4, 2024, by and between MyMD New Jersey and MyMD Delaware (the “Plan of Merger”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315224009220/0001493152-24-009220-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.